News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KeyNeurotek Pharmaceuticals Initiates Phase I Study With Canabinoid Receptor Agonist



11/8/2007 2:46:08 PM

Magdeburg, November 8, 2007 - KeyNeurotek Pharmaceuticals AG, a biotechnology company focused on the development and marketing of drugs against autoimmune diseases and degenerative disorders of the central nervous system (CNS), today announced the start of a new clinical study. The placebo-controlled, double blind, dose escalating study in healthy individuals will evaluate the tolerability and pharmacokinetics of KN38-7271, a cannabinoid receptor agonist, to treat stroke patients.

Read at ABN Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES